Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2025 | Story Somila Nazo | Photo Supplied
Prof Martin Nyaga
Prof Martin Nyaga delivered a keynote on Africa’s scientific leadership in genomics and global health at the African Academy of Sciences Summit in Accra, Ghana.

Prof Martin Nyaga, one of Africa’s foremost experts in genomics and global health, recently delivered a powerful call for Africa’s leadership in global science at the African Academy of Sciences (AAS) Summit in Accra, Ghana. 

As Head of the Next Generation Sequencing (NGS) Unit at the University of the Free State (UFS) and Director of the WHO Collaborating Centre for Vaccine Preventable Diseases Surveillance and Pathogen Genomics, Prof Nyaga urged the scientific community to recognise Africa not just as a participant in global research, but as a driver of innovation and change. 

 

A summit of vision and collaboration 

Themed Unpacking the Pact for the Future: Imperatives for Advancing Scientific Cooperation with Africa, the summit took place from 2 – 4 July 2025. Hosted by the AAS in partnership with the African Union, the Government of Ghana, the University of Ghana, and other global partners, the summit brought together leading scientists, policymakers, and international stakeholders to discuss Africa’s role in shaping the future of global science, research and innovation. 

The event was attended by high-level dignitaries, including the President of Ghana, His Excellency John Dramani Mahama, and the former President of Nigeria, His Excellency Olusegun Obasanjo – a clear indication of strong political will to prioritise science, health and innovation across the continent. 

 

Advancing Africa’s voice in global health 

On 2 July 2025, Prof Nyaga delivered his keynote address, Advances, Opportunities and Priorities for Global Health in Africa. He highlighted Africa’s growing capabilities in genomics and public health, underscoring the opportunities for scientific leadership. 

Following his address, he joined an expert panel with representatives from Tanzania, Ghana and Nigeria to discuss strategies for advancing scientific cooperation in global health. His contributions focused on: strengthening research collaborations; building capacity within Africa; increasing African ownership in health innovations, and enhancing the translation of research into policy and practice. 

Prof Nyaga also used the platform to spotlight the work of the UFS Next Generation Sequencing (UFS-NGS) Unit. As a WHO Collaborating Centre, the unit plays a critical role in pathogen tracking, monitoring vaccine-preventable diseases, and supporting public health preparedness across Africa and beyond. 

 “This engagement provided an opportunity to highlight the impactful research from the UFS-NGS Unit – not only in academic publications, but in demonstrating tangible public health benefits to policy makers,” said Prof Nyaga.  “It elevated the University of the Free State’s standing as a leader in genomic science, while opening new opportunities for collaboration for South Africa and the continent. Our research priorities are increasingly shaping global health and innovation agendas.” 

 

From Ghana to the G20 

The outcomes of the summit will feed into a communiqué to be presented at the 2025 G20 Summit, to be hosted by South Africa. Prof Nyaga’s thought leadership ensures that Africa’s scientific voice - and South Africa’s research priorities - will be represented at one of the world’s most influential multilateral platforms. 

For more information about UFS partnerships in Africa, contact the Office for International Affairs at partnerships@ufs.ac.za.  

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept